SEC Form 4 · accession 0000899243-17-008208
Blueprint Medicines Corp · BPMC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark J Levin
10% Owner
Period of report
Mar 16, 2017
Accepted (ET)
Mar 20, 2017 · 4:21 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001597264
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Mar 16, 2017 | S | 24,800 | $40.74 | D | 116,444 | D | |
| Common StockF2 | Mar 16, 2017 | S | 5,200 | $41.55 | D | 111,244 | D | |
| Common StockF3 | holding | — | — | — | 3,453,753 | I | See footnote |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.33 to $41.33, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) and (2) to this Form 4.
- F2This price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.34 to $41.84, inclusive.
- F3These shares are directly held by Third Rock Ventures II, L.P. ("TRV II"). The general partner of TRV II is Third Rock Ventures GP II, L.P. ("TRV GP II"). The general partner of TRV GP II is TRV GP II, LLC ("TRV GP II LLC"). The individual managers of TRV GP II LLC are Mark Levin ("Levin"), Kevin Starr ("Starr") and Dr. Robert Tepper ("Tepper"). Each of TRV GP II, TRV GP II LLC, Levin, Starr and Tepper disclaims beneficial ownership of the shares except to the extent of its or his pecuniary interest therein, if any, and this report shall not be deemed an admission that it or he is the beneficial owner of such shares.